Clinical Trials Browser

Terminated × prexasertib × Other hematologic neoplasm × Clear all

NCT03735446 2019-06-12

Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a Phase I Trial

Phase 1 Terminated

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute